---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-041883"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2026-06-09T20:05:26+00:00"
generated_at: "2026-06-09T20:08:58.043346+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Shareholders approve all proposals; board adopts updated director compensation program

## Summary
- Three Class III directors elected: Patrick J. Heron, Neha Krishnamohan, Todd Franklin Watanabe.
- Ernst & Young ratified as independent auditor for fiscal year 2026.
- Non-binding advisory vote approved named executive officer compensation.
- Revised director comp: $50k base retainer, $350k initial option, annual $350k award (65% options, 35% RSUs).

## SEC filing metadata
- accession: 0001628280-26-041883
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2026-06-09T20:05:26+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000162828026041883/0001628280-26-041883-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000162828026041883/arqt-20260605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-041883
- JSON: https://secwatch.observer/filing/0001628280-26-041883.json
- Plain text: https://secwatch.observer/filing/0001628280-26-041883.txt

## Key facts
- Shareholder Votes
  Arcutis Biotherapeutics, Inc. shareholders approved Non-binding advisory approval of the compensation of the Company's named executive officers at the 2026-06-05 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-05
  source text: Proposal 3. Approval, on a non-binding advisory basis of the compensation of the Company's named executive officers
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000162828026041883/0001628280-26-041883-index.htm
- Shareholder Votes
  Arcutis Biotherapeutics, Inc. shareholders approved Election of three Class III directors to hold office until the 2029 annual meeting of stockholders or until their respective successors are elected at the 2026-06-05 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-05
  source text: Proposal 1. The election of three Class III directors to hold office until the 2029 annual meeting of stockholders or until their respective successors are elected
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000162828026041883/0001628280-26-041883-index.htm
- Shareholder Votes
  Arcutis Biotherapeutics, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-05 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-05
  source text: Proposal 2. The ratification of the selection, by the Audit Committee of the Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000162828026041883/0001628280-26-041883-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.